Matt Segall: Difference between revisions

From Crucible Network Research Projects
Jump to navigationJump to search
(Created page with "Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new interactive approaches to drug design that exploited quantum mechanical modelling...")
 
No edit summary
Line 1: Line 1:
Founder of Optibrium, previously at [[ArQule]], Matt commissioned a Crucible team to develop new interactive approaches to drug design that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.
Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new [[design approaches to drug discovery]] that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.

Revision as of 07:23, 10 August 2011

Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new design approaches to drug discovery that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.